PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status

Ben Fulton; Susan C Short; Allan James; Stefan Nowicki; Catherine McBain; Sarah Jefferies; Caroline Kelly; Jon Stobo; Anna Morris; Aoife Williamson; Anthony J Chalmers

doi:10.1016/j.ctro.2017.11.003

PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status

Clin Transl Radiat Oncol. 2017 Nov 21:8:12-16. doi: 10.1016/j.ctro.2017.11.003. eCollection 2018 Jan.

Authors

Affiliations

¹ Institute of Cancer Sciences, University of Glasgow, UK.
² Leeds Institute of Cancer and Pathology, University of Leeds, UK.
³ Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde, Glasgow, UK.
⁴ Christie NHS Foundation Trust, Manchester, UK.
⁵ Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Abstract

Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform treatment schedules.

Keywords: Dose escalation; Glioblastoma; O6-methylguanine methyltransferase; Olaparib; Poly(ADP-ribose) polymerase; Radiosensitizer; Radiotherapy.

Abstract

Grants and funding